DCGI approves Phase 2,3 clinical trial of Covaxin in the age group of 2 to 18 Years
New Delhi, The National Regulator of the country, the Drugs Controller General of India (DCGI), after careful examination, has accepted the recommendation of Subject Expert Committee (SEC) and accorded permission …
DCGI approves Phase 2,3 clinical trial of Covaxin in the age group of 2 to 18 Years Read More